FAQ: Which children with early puberty actually need testing and treatment?

The Endocrine Society has released a new clinical practice guideline addressing the diagnosis and management of central precocious puberty (CPP), offering clinicians updated, evidence-based direction on when evaluation and treatment are warranted and when watchful waiting may be more appropriate.¹ The guideline was developed by a multidisciplinary panel using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach to address 10 priority clinical questions, and it is co-sponsored by the American Academy of Pediatrics, the Brazilian Society of Endocrinology and Metabolism, the European Society of Endocrinology, the European Society for Paediatric Endocrinology, the Latin American Society for Pediatric Endocrinology, the Pediatric Endocrine Society, and the Pediatric Pharmacy Association.¹

CPP occurs when the hypothalamic-pituitary-gonadal axis activates prematurely, traditionally defined as the onset of secondary sexual characteristics before age 8 years in girls and age 9 years in boys.¹ The condition is roughly 10 times more common in girls and has been linked to short adult stature, psychosocial difficulties, and elevated long-term cardiometabolic and cancer risk.¹ However, as population-level pubertal timing has trended earlier in recent decades, the panel found that some children who meet the traditional definition of CPP, such as older girls with slowly progressing puberty, may not benefit from the same intensity of diagnostic workup or gonadotropin-releasing hormone agonist (GnRHa) treatment historically applied to all patients.¹ ² The guideline proposes 2 clinical algorithms, 1 for diagnosis and 1 for treatment, intended to help clinicians individualize care.¹

Q: When should girls with breast development between ages 7.0 and 8.0 years undergo full diagnostic evaluation?

A: The panel suggests watchful waiting with physical examinations every 4 to 6 months, rather than immediately ordering laboratory testing or imaging, for girls who present with Tanner stage B2 breast development between ages 7.0 and 8.0 years.¹ This recommendation is conditional and based on very low certainty evidence.¹ Immediate evaluation remains appropriate for girls who present with Tanner B3 or higher, who progress to B3 during observation, who show growth acceleration (pubertal growth velocity greater than 6 cm/year), or who have central nervous system (CNS) symptoms such as headaches, seizures, or visual field deficits.¹ The recommendation does not apply to girls with findings suggestive of other conditions, such as congenital adrenal hyperplasia or McCune-Albright syndrome.¹

“Children who start puberty earlier than usual should be carefully evaluated so they receive the right care at the right time, without unnecessary tests or treatment,” said writing group chair Ana Claudia Latronico, MD, PhD, of the University of São Paulo.²

Q: Should girls younger than 7 years with early breast development be observed before testing begins?

A: Yes. For girls younger than age 7 years with initial Tanner B2 breast development, the panel suggests a 4- to 6-month observation period, consisting of periodic growth and Tanner staging reassessment, to distinguish unsustained or slowly progressive puberty from rapidly progressive puberty before diagnostic testing begins.¹ Supporting evidence from case series found that 33% to 66% of girls in this age range had rapidly progressive disease, while the remainder had unsustained or slowly progressive puberty that often resolved or proceeded to a normal adult height without treatment.¹ As with the previous recommendation, immediate evaluation is warranted for girls with rapid progression to Tanner B3, growth acceleration, or CNS findings.¹

Q: What is the recommended first-line hormonal test for diagnosing CPP?

A: The panel suggests starting with a basal luteinizing hormone (LH) concentration measured by an ultrasensitive assay rather than immediately performing a gonadotropin-releasing hormone (GnRH) or GnRH agonist stimulation test.¹ Across the reviewed studies, higher basal LH values, generally above 0.2 to 0.3 IU/L depending on Tanner stage and assay method, predicted a positive stimulation test result, and reported sensitivity ranged from 42% to 94% while specificity ranged from 70% to 100%.¹ When basal LH is low but clinical suspicion for CPP remains high, particularly in rapidly progressive cases, the panel suggests proceeding to GnRH/GnRHa stimulation testing as the next step.¹ First-morning sampling (8:00-10:00 AM) may be optimal but is not required, as the panel judged basal LH testing acceptable at any time of day to improve feasibility.¹

“We give clinicians suggestions that avoid unnecessary or invasive testing and treatment, such as sometimes initially using a period of observation by their health care provider, using simpler testing methods and individualizing treatment when indicated,” said writing group co-chair Stephanie Roberts, MD, of Boston Children's Hospital.²

Q: Is brain MRI necessary for every child diagnosed with CPP?

A: No. The panel suggests against routinely performing brain MRI in girls ages 6.0 to 8.0 years and boys ages 8.0 to 9.0 years who have CPP without CNS symptoms or signs.¹ A review of 35 uncontrolled studies comprising 5541 children found that pathologic MRI findings (brain tumors or hypothalamic hamartomas) occurred in just 1% of girls ages 6.0 to 8.0 years and 0% of boys ages 8.0 to 9.0 years, compared with substantially higher rates in younger children and in boys under age 8 years.¹ This recommendation does not apply to younger patients or to children of any age with CNS symptoms such as headaches, seizures, or visual field deficits, for whom brain MRI remains indicated.¹

Q: Should genetic testing be performed routinely in children with CPP?

A: The panel suggests against routine genetic testing, including sequencing for loss-of-function variants in MKRN3, DLK1, or MECP2, for children with CPP.¹ However, genetic testing should be considered through shared decision-making for children with familial CPP, since diagnostic yield is markedly higher in that subgroup; MKRN3 variants, for example, account for approximately 9% of apparently idiopathic cases but 33% to 46% of familial cases.¹ Family history (odds ratio [OR], 3.3; 95% CI, 1.3-8.3; P = .01) and coexisting neurodevelopmental disorders (OR, 4.1; 95% CI, 1.3-13.5; P = .02) were identified as predictors of a genetic etiology in 1 cohort study.¹ The panel noted that CPP due to MKRN3 mutations is clinically indistinguishable from idiopathic CPP, while DLK1-related CPP has been associated with a higher risk of adult obesity and type 2 diabetes.¹

Q: Should all children with CPP receive GnRH agonist treatment?

A: For many, yes, but not all. The panel suggests GnRHa treatment for many children with CPP, while cautioning that certain subgroups, including girls ages 7.0 to 8.0 years with slowly progressive CPP and children who are at or beyond their pubertal growth spurt peak, are unlikely to gain a meaningful height benefit.¹ Meta-analysis of 14 studies involving 1017 treated girls and 480 untreated controls found a mean adult height difference of +2.7 cm (95% CI, 1.1-4.4) favoring treatment, with a larger benefit (+3.9 cm; 95% CI, 0.9-6.8) among those treated for 3 years or longer, a duration typically associated with earlier treatment initiation.¹ Treatment was also associated with delayed menarche, occurring at a weighted mean of 1.3 years later (95% CI, 1.07-1.96) compared with untreated girls.¹ The panel found no meaningful effect of treatment on body mass index and stressed that recommendations for boys were extrapolated from girls-only evidence, since direct data in boys were lacking.¹ Shared decision-making, incorporating patient and family values alongside anticipated height and psychosocial benefits, was emphasized throughout.¹

Q: Should treatment start with a monthly formulation or a longer-acting GnRH agonist?

A: In patients expected to use a long-acting formulation (3-month, 6-month, or the 12-month subcutaneous implant) over the long term, the panel suggests initiating therapy directly with that long-acting formulation rather than starting with a monthly injectable first.¹ A synthesis of 3 randomized trials and 7 observational studies involving 759 patients found trivial differences between monthly and long-acting formulations in gonadotropin suppression, growth velocity, and the proportion of patients achieving adequate LH suppression.¹ Cost and access vary considerably; average annual wholesale prices for GnRH agonists in the United States ranged from approximately $30,000 to $60,000 as of 2025, depending on formulation.¹ Patients and families who anticipate long-term use of monthly formulations should still begin treatment with the monthly option.¹

Q: Is routine biochemical monitoring needed once treatment has started?

A: No. The panel suggests against routine biochemical testing, such as LH or sex steroid concentrations, to monitor pubertal suppression in children without clinical signs of treatment failure.¹ Instead, the panel recommends relying on interval clinical assessment, including growth velocity, Tanner staging, and annual bone age evaluation.¹ Biochemical testing remains appropriate when treatment failure is clinically suspected, such as progression in breast or testicular development or persistent pubertal growth velocity, and adherence should be carefully assessed before altering the treatment regimen.¹ The panel noted that standard GnRHa doses occasionally fail to achieve biochemical suppression without producing any clinical evidence of pubertal progression, raising concern that routine biochemical monitoring alone could lead to overtreatment.¹

Q: Does adding growth hormone therapy improve adult height in children treated with GnRH agonists?

A: No meaningful benefit was found. The panel suggests against the routine addition of growth hormone (GH) to GnRHa therapy.¹ Meta-analysis of 8 retrospective cohort studies comprising 1024 girls, 276 of whom received combination therapy, found a mean adult height difference of only −0.16 cm (95% CI, −2.12 to 1.81) with added GH, a difference the panel judged trivial.¹ A subgroup analysis by predicted adult height also showed no significant difference between patients with lower versus higher baseline predicted height (P = .33).¹ Combination therapy substantially increased cost in the studies reviewed; 1 analysis found total costs nearly 3.8-fold higher with combined therapy compared with GnRHa alone, without a statistically significant gain in predicted adult height.¹ This recommendation does not apply to children with CPP who also have a distinct, approved indication for GH therapy, such as GH deficiency or Prader-Willi syndrome.¹

Q: When should GnRH agonist treatment be discontinued?

A: The panel suggests against routinely continuing GnRHa treatment beyond chronologic age 10.0 to 11.0 years in girls or 11.0 to 12.0 years in boys, and/or bone age 11.0 to 12.0 years in girls or 12.0 to 13.0 years in boys.¹ Indirect evidence suggests that adult height outcomes are more strongly influenced by patient characteristics at treatment initiation, particularly age at CPP onset, than by the age at which treatment is discontinued.¹ Time to menarche after stopping treatment averages 12 to 18 months and does not appear to vary meaningfully by age at discontinuation.¹ The panel noted that individualized factors, including growth trajectory, psychosocial considerations, and neurocognitive impairment, may justify continuing treatment beyond these thresholds in select patients, underscoring the importance of shared decision-making.¹

References

1. Latronico AC, Roberts SA, Alonzo M, et al. Central precocious puberty: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. Published June 13, 2026. https://doi.org/10.1210/clinem/dgag168.

2. Not all children with early puberty need the same level of testing or treatment. Endocrine Society. Published June 9, 2026. https://www.newswise.com/articles/not-all-children-with-early-puberty-need-the-same-level-of-testing-or-treatment.